DMEMEDS shared post via Reuters: Aerie Pharma's combo eye drug succeeds, shares soar

(Reuters) - Drug developer Aerie Pharmaceuticals Inc said its single-drop eye treatment was shown to be superior to each of its two components in a mid-stage trial, sending its shares up by about 24 percent in premarket trading. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/9NYAlPYOyc0/story01.htm

Read More